Varilrix

Varilrix is a live attenuated varicella vaccine derived from the Oka strain, designed to protect against chickenpox. This vaccine is produced in human diploid cells (MRC-5) and is administered via injection. It is commonly used for immunization in children and adults.

Varilrix is used to prevent varicella (chickenpox) infection caused by the varicella-zoster virus. It is typically recommended for children over 12 months of age and adults who have not had chickenpox or received prior vaccination. The vaccine helps the immune system recognize and fight the virus, reducing the risk of infection or severe disease. It may also be used for post-exposure prophylaxis in certain cases.

After vaccination with Varilrix, the immune system responds by producing antibodies against the varicella-zoster virus. This immune response may cause mild effects such as soreness at the injection site, low-grade fever, or a mild rash resembling chickenpox. These effects are generally short-lived and indicate the vaccine is working to build immunity.

Varilrix should not be administered to individuals with a known allergy to any component of the vaccine, including neomycin or gelatin. It is important to inform the healthcare provider about any current illnesses, immune system disorders, or recent blood transfusions. Pregnant women should avoid vaccination unless specifically advised by a healthcare professional.

Varilrix may interact with immunosuppressive therapies, including corticosteroids or chemotherapy, which can reduce the vaccine's effectiveness. Live vaccines should not be given within 4 weeks of another live vaccine unless approved by a healthcare provider. Blood products or immune globulins may also interfere with the vaccine's response.